Abstract:Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB), an immunosuppressive tumor microenvironment (TME) and development of drug resistance are key barriers to successful glioma treatment. Since gliomas occur through sequential acquisition of genetic alterations, gene therapy, which enables to modification of the genetic make-up of target cells, appears to be a promising approach to overcome the obstacles encountered by current therapeutic strategies. Gene therapy is a rapidly evolving field with the ultimate goal of achieving specific delivery of therapeutic molecules using either viral or non-viral delivery vehicles. Gene therapy can also be used to enhance immune responses to tumor antigens, reprogram the TME aiming at blocking glioma-mediated immunosuppression and normalize angiogenesis. Nano-particles-mediated gene therapy is currently being developed to overcome the BBB for glioma treatment. Another approach to enhance the anti-glioma efficacy is the implementation of viro-immunotherapy using oncolytic viruses, which are immunogenic. Oncolytic viruses kill tumor cells due to cancer cell-specific viral replication, and can also initiate an anti-tumor immunity. However, concerns still remain related to off target effects, and therapeutic and transduction efficiency. In this review, we describe the rationale and strategies as well as advantages and disadvantages of current gene therapy approaches against gliomas in clinical and preclinical studies. This includes different delivery systems comprising of viral, and non-viral delivery platforms along with suicide/prodrug, oncolytic, cytokine, and tumor suppressor-mediated gene therapy approaches. In addition, advances in glioma treatment through BBB-disruptive gene therapy and anti-EGFRvIII/VEGFR gene therapy are also discussed. Finally, we discuss the results of gene therapy-mediated human clinical trials for gliomas. In summary, we highlight the progress, prospects and remaining challenges of gene therapies aiming at broadening our understanding and highlighting the therapeutic arsenal for GBM.

Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.

Novel gene-directed enzyme prodrug therapies against prostate cancer

Section Review—Oncologic, Endocrine & Metabolic: Gene Therapy Strategies for Cancer

Gene-Directed Enzyme Prodrug Therapy by Dendrimer-Like Mesoporous Silica Nanoparticles against Tumor Cells

Advances in gene therapy for high-grade glioma: a review of the clinical evidence

Gene therapy in glioblastoma multiforme: Can it be a role changer?

Current Approaches for Glioma Gene Therapy and Virotherapy

Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy

Designing cytochrome P450 enzymes for use in cancer gene therapy

Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models

Gene Therapy for Cancer: What Have We Done and Where Are We Going?

Current Status and Future Possibilities

Recombinant horseradish peroxidase variants for targeted cancer treatment

Three decades of gene therapy development: milestones and prospects

Twenty Years of Gendicine® Rad-P53 Cancer Gene Therapy: the First-in-class Human Cancer Gene Therapy in the Era of Personalized Oncology

Gene Therapy for High Grade Glioma: The Clinical Experience

Gene therapy - once just a dream, now a reality

Protein degraders enter the clinic — a new approach to cancer therapy

Engineering Gene Therapy: Advances and Barriers

A primer to gene therapy: Progress, prospects, and problems

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management